Annexin V Reversal of CTL Exhaustion in HIV
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiretroviral therapies, such as HAART, cannot clear HIV reservoirs in quiescent cells like monocytes/macrophages, leading to persistent viral infection due to cytotoxic T lymphocyte (CTL) exhaustion and anergy, which is not effectively addressed by existing treatments.
Innovation Solution
Administration of an effective dose of annexin V protein, including recombinant human annexin V and its derivatives, to reduce T cell exhaustion by binding to phosphatidylserine on infected cells, potentially combined with HAART, to enhance CTL function and reduce viral load.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If HAART treatment is used to inhibit viral spread and proliferation, then viral load is reduced in dividing cells, but virus reservoirs in quiescent cells cannot be cleared
Solution Approach 1:
The patent introduces annexin V as an intermediary substance that binds to phosphatidylserine on the surface of infected cells, particularly quiescent cells like monocytes and macrophages. This binding action mediates the clearance of virus reservoirs that HAART cannot directly access, thereby resolving the contradiction between reducing viral load and clearing persistent reservoirs.
Solution Approach 2:
The patent extracts the function of clearing quiescent cell reservoirs from the HAART system and assigns it to annexin V. By separating this function, the system can maintain HAART for suppressing viral replication in dividing cells while using annexin V specifically to clear reservoirs in quiescent cells, thus resolving the limitation of HAART alone.
2Object-affected harmful factors
If CTL exhaustion occurs to control viral infection, then immune activation is reduced, but ability to clear virus reservoirs is lost
Solution Approach 1:
The patent converts the harmful effect of phosphatidylserine exposure (which causes CTL exhaustion and anergy) into a beneficial target for annexin V binding. By having annexin V bind to phosphatidylserine on infected cells, the system transforms the exhaustion signal into a mechanism for selective clearance of reservoirs while maintaining overall immune control.
Solution Approach 2:
The patent changes the functional parameter of phosphatidylserine from a marker of cell death/exhaustion to a target for therapeutic binding. This parameter change allows the system to distinguish between exhausted CTLs (which need preservation) and infected quiescent cells (which need clearance), resolving the contradiction between maintaining immune control and clearing reservoirs.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Annexin V treatment significantly increases HIV-specific CTL expansion, granzyme B expression, and CD25 activation, specifically targeting exhausted T cells, resulting in a substantial reduction of HIV viral load and T cell exhaustion, while maintaining non-exhausted CTL functionality.
Implementation Method 1
annexin V, a human 36 kDa protein with a nanomolar affinity for membrane bound PS
Data Source
AI summary
Methods are provided for treating an individual with cytotoxic T lymphocyte exhaustion by administering an effective dose of an annexin V agent. In some embodiments, the individual undergoing treatment is infected with HIV. The individual may be treated with highly active antiretroviral therapy (HAART).